Medicines Company To Undertake Two Hirulog Studies After Cmte. Rejection
Executive Summary
The Medicines Company is prepared to go ahead with two previously planned studies for Hirulog (bivalirudin) following an FDA advisory committee rejection of the anticoagulant.
You may also be interested in...
The Medicines Company Angiomax
FDA issues "approvable" letter May 11 for bivalirudin as an anticoagulant for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. In October 1998, FDA's Cardiovascular and Renal Drugs Advisory Committee declined to recommend the anticoagulant, formerly Hirulog, for approval (1"The Pink Sheet" Nov 2, 1998, p. 19)
The Medicines Company Angiomax
FDA issues "approvable" letter May 11 for bivalirudin as an anticoagulant for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. In October 1998, FDA's Cardiovascular and Renal Drugs Advisory Committee declined to recommend the anticoagulant, formerly Hirulog, for approval (1"The Pink Sheet" Nov 2, 1998, p. 19)
Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights
Rhone-Poulenc Rorer would divest its direct thrombin inhibitor candidate Revasc (desirudin) in order to complete its merger with Hoechst Marion Roussel into Aventis, a Dec. 7 consent order provisionally accepted by the Federal Trade Commission states.